RecruitingNot applicableNCT06792604
Host Genome Methylation: a Screening Tool in Anal Cancer Detection
Studying Carcinoma of the anal canal
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Intervention
- Anal self-sampling (smear)(device)
- Enrollment
- 770 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (9)
- Cardiovascular Surgery and Transplantation Department Bichat-Claude Bernard Hospital, Paris, Île-de-France Region, France
- Dermatology Department, Paris, Île-de-France Region, France
- Gynecology and Obstetrics Department Bichat-Claude Bernard Hospital, Paris, Île-de-France Region, France
- Hepato-Gastroenterology, Digestive Oncology, and Proctology Department Bichat-Claude Bernard Hospital, Paris, Île-de-France Region, France
- Infectious and Tropical Diseases Department Bichat-Claude Bernard Hospital, Paris, Île-de-France Region, France
- Nephrology Department Bichat-Claude Bernard Hospital, Paris, Île-de-France Region, France
- Pathological Anatomy and Cytology Department Bichat-Claude Hospital, Paris, Île-de-France Region, France
- Pulmonology B and Lung Transplantation Department Bichat-Claude Bernard Hospital, Paris, Île-de-France Region, France
- Virology Department Bichat-Claude Bernard Hospital, Paris, Île-de-France Region, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06792604 on ClinicalTrials.govOther trials for Carcinoma of the anal canal
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07029152Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure ProphylaxisUniversitair Ziekenhuis Brussel
- ACTIVE NOT RECRUITINGPHASE3NCT06866574A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese MalesXiamen University
- RECRUITINGPHASE2NCT06640283Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical OutcomesInstituto do Cancer do Estado de São Paulo
- RECRUITINGPHASE3NCT06207981Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCAFederation Francophone de Cancerologie Digestive
- RECRUITINGPHASE2NCT05661188Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)Grupo Espanol Multidisciplinario del Cancer Digestivo
- RECRUITINGNCT06327568Anal Cancer and/or Precancer Screening: Performance Analysis of the BD Onclarity™ HPV Assay on Anal SpecimensEuropean Institute of Oncology
- RECRUITINGNCT05438836Re-optimization Based Online Adaptive Radiotherapy of Anal CancerHerlev Hospital
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04432597HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated CancersNational Cancer Institute (NCI)